Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Cancer - United States
doi 10.1002/cncr.25792
Full Text
Open PDFAbstract
Available in full text
Date
December 14, 2010
Authors
Publisher
Wiley